Atara Biotherapeutics, Inc. (0HIY.L)
USD 6.94
(2.46%)
USD 6.94
(2.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -276 Million USD | 4.01% |
| 2022 | -280.51 Million USD | 17.61% |
| 2021 | -340.46 Million USD | -10.16% |
| 2020 | -309.05 Million USD | -4.52% |
| 2019 | -295.68 Million USD | -24.7% |
| 2018 | -237.11 Million USD | -95.1% |
| 2017 | -121.53 Million USD | -49.59% |
| 2016 | -81.24 Million USD | -39.0% |
| 2015 | -58.44 Million USD | -107.59% |
| 2014 | -28.15 Million USD | -226.83% |
| 2013 | -8.61 Million USD | -167.13% |
| 2012 | -3.22 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -17.87 Million USD | 31.19% |
| 2024 Q1 | -26.49 Million USD | 50.27% |
| 2023 Q1 | -75.01 Million USD | 0.69% |
| 2023 FY | -269.27 Million USD | 4.01% |
| 2023 Q4 | -53.27 Million USD | 23.47% |
| 2023 Q3 | -69.61 Million USD | 2.52% |
| 2023 Q2 | -71.41 Million USD | 4.8% |
| 2022 Q4 | -75.53 Million USD | 10.73% |
| 2022 Q1 | -88.22 Million USD | 8.0% |
| 2022 Q2 | -32.13 Million USD | 63.58% |
| 2022 FY | -280.51 Million USD | 17.61% |
| 2022 Q3 | -84.62 Million USD | -163.36% |
| 2021 Q3 | -84.81 Million USD | -0.96% |
| 2021 Q4 | -95.89 Million USD | -13.06% |
| 2021 Q1 | -78.24 Million USD | 4.23% |
| 2021 FY | -340.46 Million USD | -10.16% |
| 2021 Q2 | -84 Million USD | -7.36% |
| 2020 Q4 | -81.69 Million USD | -9.36% |
| 2020 Q1 | -74.69 Million USD | 6.28% |
| 2020 Q2 | -77.95 Million USD | -4.36% |
| 2020 Q3 | -74.7 Million USD | 4.16% |
| 2020 FY | -309.05 Million USD | -4.52% |
| 2019 Q2 | -75.53 Million USD | -11.26% |
| 2019 Q1 | -67.89 Million USD | 17.02% |
| 2019 FY | -295.68 Million USD | -24.7% |
| 2019 Q4 | -79.69 Million USD | -9.84% |
| 2019 Q3 | -72.55 Million USD | 3.94% |
| 2018 Q3 | -60.22 Million USD | -14.44% |
| 2018 Q1 | -42.45 Million USD | -18.57% |
| 2018 FY | -237.11 Million USD | -95.1% |
| 2018 Q4 | -81.81 Million USD | -35.86% |
| 2018 Q2 | -52.62 Million USD | -23.96% |
| 2017 Q1 | -26.16 Million USD | -39.5% |
| 2017 FY | -121.53 Million USD | -49.59% |
| 2017 Q4 | -35.8 Million USD | -13.08% |
| 2017 Q3 | -31.66 Million USD | -13.44% |
| 2017 Q2 | -27.9 Million USD | -6.68% |
| 2016 Q2 | -19.48 Million USD | -14.21% |
| 2016 Q1 | -17.06 Million USD | 21.63% |
| 2016 FY | -81.24 Million USD | -39.0% |
| 2016 Q4 | -18.75 Million USD | 27.71% |
| 2016 Q3 | -25.94 Million USD | -33.14% |
| 2015 FY | -58.44 Million USD | -107.59% |
| 2015 Q2 | -15.1 Million USD | -62.26% |
| 2015 Q1 | -9.31 Million USD | 12.13% |
| 2015 Q4 | -21.77 Million USD | -77.58% |
| 2015 Q3 | -12.25 Million USD | 18.86% |
| 2014 Q2 | -4.53 Million USD | 35.93% |
| 2014 Q4 | -10.59 Million USD | -78.11% |
| 2014 FY | -28.15 Million USD | -226.83% |
| 2014 Q3 | -5.94 Million USD | -31.21% |
| 2014 Q1 | -7.07 Million USD | -107.11% |
| 2013 Q1 | -1.28 Million USD | 0.0% |
| 2013 Q3 | -2.55 Million USD | -87.51% |
| 2013 Q4 | -3.41 Million USD | -33.89% |
| 2013 FY | -8.61 Million USD | -167.13% |
| 2013 Q2 | -1.36 Million USD | -5.83% |
| 2012 FY | -3.22 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 29.498% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -472.627% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -149.52% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 113.961% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -3.055% |
| Homology Medicines, Inc. | -48.25 Million USD | -471.974% |
| Imunon, Inc. | -21.03 Million USD | -1212.413% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 40.072% |
| uniQure N.V. | -282.87 Million USD | 2.427% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -183.499% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -275.549% |
| bluebird bio, Inc. | -244.26 Million USD | -12.996% |
| Blueprint Medicines Corporation | -486.27 Million USD | 43.241% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -127.175% |
| Adicet Bio, Inc. | -152.03 Million USD | -81.538% |
| Dynavax Technologies Corporation | -37.02 Million USD | -645.398% |
| Geron Corporation | -193.94 Million USD | -42.312% |
| Illumina, Inc. | -1.06 Billion USD | 74.181% |
| Myriad Genetics, Inc. | -123.7 Million USD | -123.125% |
| Verastem, Inc. | -92.08 Million USD | -199.733% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 106.408% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 104.024% |
| Biogen Inc. | 1.29 Billion USD | 121.284% |
| Nektar Therapeutics | -137.42 Million USD | -100.841% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -173.742% |
| Perrigo Company plc | 151.9 Million USD | 281.702% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -517.919% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 210.006% |
| Editas Medicine, Inc. | -169.18 Million USD | -63.142% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -77.424% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 125.385% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -5138.299% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 98.039% |
| Waters Corporation | 817.67 Million USD | 133.755% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -512.295% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 241.948% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -0.73% |
| Evolus, Inc. | -49.23 Million USD | -460.612% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 106.82% |
| FibroGen, Inc. | -281.81 Million USD | 2.061% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 120.445% |
| OPKO Health, Inc. | -157.02 Million USD | -75.776% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 2.186% |
| Exelixis, Inc. | 170.88 Million USD | 261.516% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -395.025% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 46.437% |
| Zoetis Inc. | 3.06 Billion USD | 108.993% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -19.058% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -604.942% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 21.973% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 357.271% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 181.762% |
| Insmed Incorporated | -709.62 Million USD | 61.105% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1437.692% |
| Incyte Corporation | 620.52 Million USD | 144.479% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 62.004% |